We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft. Ten of these patients received two additional courses of rituximab after the transplant. Seven experienced severe neutropenia after the second administration. Our data suggest that early administration of rituximab following a transplant may favor the onset of neutropenia.

Cairoli, R., Grillo, G., Tedeschi, A., D'Avanzo, G., Marenco, P., Morra, E. (2004). High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. HAEMATOLOGICA, 89(3), 361-363.

High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation

Cairoli R
;
2004

Abstract

We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft. Ten of these patients received two additional courses of rituximab after the transplant. Seven experienced severe neutropenia after the second administration. Our data suggest that early administration of rituximab following a transplant may favor the onset of neutropenia.
Articolo in rivista - Articolo scientifico
Autologous transplant; Neutropenia; Rituximab;
English
2004
89
3
361
363
reserved
Cairoli, R., Grillo, G., Tedeschi, A., D'Avanzo, G., Marenco, P., Morra, E. (2004). High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. HAEMATOLOGICA, 89(3), 361-363.
File in questo prodotto:
File Dimensione Formato  
Cairoli-2004-Haematologica-VoR.pdf

Solo gestori archivio

Descrizione: Letter to the Editor
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 201.37 kB
Formato Adobe PDF
201.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/408702
Citazioni
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
Social impact